knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 23:06:35 - browse：79631

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： 5 takeaways from STAT's examination of Zynex Medical

Wikipedia

WSS

Sage considers ways to reduce costs following FDA rejection

How CRISPR works, explained in two minutes

Election results set back Medicaid expansion plans

Teladoc has a new CEO, but challenges remain the same

NFL doctors' conflicts of interest could endanger players, report says

How CRISPR works, explained in two minutes

focus

knowledge

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Activists slam private health insurers over coverage restrictions

My daughter's legacy lives on through her writing, phage therapy

Wildfire smoke exposes gaps in outdoor worker protections

NIH tests clinical research in primary care with $30 million program

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Wildfire smoke exposes gaps in outdoor worker protections

NIH tests clinical research in primary care with $30 million program

knowledge

Sage considers ways to reduce costs following FDA rejection

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Cheap, fast test for Zika and dengue could cost just $1

NIH tests clinical research in primary care with $30 million program

Feed a cold, starve a fever? Here’s what science says

Failure, not just success, should guide future doctors

entertainment

Wikipedia

focus

focus